Total Payments
$14,128
2023 Payments
$11,538
Companies
5
Transactions
14
Payment Breakdown by Category
Research$14,095 (99.8%)
Food & Beverage$33.22 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,095 | 12 | 99.8% |
| Food and Beverage | $33.22 | 2 | 0.2% |
Payments by Type
Research
$14,095
12 transactions
General
$33.22
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $9,683 | 5 | $0 (2023) |
| Allergan Inc. | $2,557 | 6 | $0 (2017) |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,855 | 1 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $19.75 | 1 | $0 (2017) |
| Orexo US, Inc. | $13.47 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $11,538 | 6 | PFIZER INC. ($9,683) |
| 2020 | $13.47 | 1 | Orexo US, Inc. ($13.47) |
| 2017 | $2,577 | 7 | Allergan Inc. ($2,557) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,266.08 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,214.61 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $2,995.40 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $2,206.94 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/03/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 04/06/2023 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,855.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 12/11/2020 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $13.47 | General |
| Category: Addiction Medicine | ||||||
| 06/28/2017 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: CNS | ||||||
| 03/16/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $345.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 01/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $620.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 01/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $356.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 01/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $260.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 01/24/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $620.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | ||||||
| 01/24/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $356.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $9,683 | 5 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,855 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $1,581 | 4 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $976.00 | 2 |
About Dr. Stephen Poland, M.D
Dr. Stephen Poland, M.D is a Psychiatry healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548277395.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Poland, M.D has received a total of $14,128 in payments from pharmaceutical and medical device companies, with $11,538 received in 2023. These payments were reported across 14 transactions from 5 companies. The most common payment nature is "" ($14,095).
Ad
Practice Information
- Specialty Psychiatry
- Location Cincinnati, OH
- Active Since 08/02/2006
- Last Updated 07/12/2017
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1548277395
Products in Payments
- ZAVZPRET (Drug) $11,538
- LATUDA (Drug) $19.75
- Zubsolv (Drug) $13.47
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Cincinnati
Henry Nasrallah, Md, MD
Psychiatry — Payments: $4.0M
Psychiatry $4.0M
Dr. Tracey Skale, M.d, M.D
Psychiatry — Payments: $652,367
Psychiatry $652,367
Paul Keck, Md, MD
Psychiatry — Payments: $568,675
Psychiatry $568,675
Dr. Caleb Adler, Md, MD
Psychiatry — Payments: $133,953
Psychiatry $133,953
Helen Farrell, Md, MD
Psychiatry — Payments: $132,909
Psychiatry $132,909
Melissa Delbello, Md, MD
Psychiatry — Payments: $104,547
Psychiatry $104,547